Linked Life Data

9399217

Source:http://linkedlifedata.com/resource/pubmed/id/9399217

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:9399217rdf:typepubmed:Citationlld:pubmed
pubmed-article:9399217lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:9399217lifeskim:mentionsumls-concept:C1257890lld:lifeskim
pubmed-article:9399217lifeskim:mentionsumls-concept:C0030567lld:lifeskim
pubmed-article:9399217lifeskim:mentionsumls-concept:C0023570lld:lifeskim
pubmed-article:9399217lifeskim:mentionsumls-concept:C0246330lld:lifeskim
pubmed-article:9399217lifeskim:mentionsumls-concept:C1524062lld:lifeskim
pubmed-article:9399217lifeskim:mentionsumls-concept:C0205360lld:lifeskim
pubmed-article:9399217lifeskim:mentionsumls-concept:C0339897lld:lifeskim
pubmed-article:9399217lifeskim:mentionsumls-concept:C0599724lld:lifeskim
pubmed-article:9399217lifeskim:mentionsumls-concept:C2603343lld:lifeskim
pubmed-article:9399217pubmed:issue6lld:pubmed
pubmed-article:9399217pubmed:dateCreated1998-2-10lld:pubmed
pubmed-article:9399217pubmed:abstractTextThe primary objective of this study was to assess the effect of tolcapone on levodopa dosage in parkinsonian patients whose "wearing-off" phenomenon has been controlled with more frequent levodopa dosage. After a 1-week placebo run-in, 97 patients were assigned randomly to receive placebo or tolcapone 200 or 400 mg three times daily (t.i.d.). Levodopa dosage was reduced by -35% on day 1 of study and subsequently retitrated as required. After 6 weeks, the tolcapone groups crossed over to receive the other dose for a further 3 weeks for exploratory purposes. Both tolcapone groups had greater reductions in levodopa dosage than the placebo group at week 6 (not statistically different). The 200-mg t.i.d. group showed greatest improvement in estimated mean scores for all efficacy parameters (p < 0.05 versus placebo for change in Unified Parkinson's Disease Rating Scale Subscale II). Fewer dopaminergic and nondopaminergic adverse events were associated with tolcapone 200 mg t.i.d. than with tolcapone 400 mg t.i.d. The most frequently reported dopaminergic adverse events were nausea, cramps, dyskinesia, and dystonia. The most frequently reported unanticipated adverse event was diarrhea. Tolcapone 200 mg t.i.d. may provide additional benefit to patients with moderately advanced Parkinson's disease with treated "wearing-off" phenomenon.lld:pubmed
pubmed-article:9399217pubmed:languageenglld:pubmed
pubmed-article:9399217pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9399217pubmed:citationSubsetIMlld:pubmed
pubmed-article:9399217pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9399217pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9399217pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9399217pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9399217pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9399217pubmed:statusMEDLINElld:pubmed
pubmed-article:9399217pubmed:monthNovlld:pubmed
pubmed-article:9399217pubmed:issn0885-3185lld:pubmed
pubmed-article:9399217pubmed:authorpubmed-author:OlssonJ EJElld:pubmed
pubmed-article:9399217pubmed:authorpubmed-author:FindleyL JLJlld:pubmed
pubmed-article:9399217pubmed:authorpubmed-author:DupontEElld:pubmed
pubmed-article:9399217pubmed:authorpubmed-author:BurgunderJ...lld:pubmed
pubmed-article:9399217pubmed:authorpubmed-author:DorflingerEElld:pubmed
pubmed-article:9399217pubmed:issnTypePrintlld:pubmed
pubmed-article:9399217pubmed:volume12lld:pubmed
pubmed-article:9399217pubmed:ownerNLMlld:pubmed
pubmed-article:9399217pubmed:authorsCompleteYlld:pubmed
pubmed-article:9399217pubmed:pagination928-34lld:pubmed
pubmed-article:9399217pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:9399217pubmed:meshHeadingpubmed-meshheading:9399217-...lld:pubmed
pubmed-article:9399217pubmed:meshHeadingpubmed-meshheading:9399217-...lld:pubmed
pubmed-article:9399217pubmed:meshHeadingpubmed-meshheading:9399217-...lld:pubmed
pubmed-article:9399217pubmed:meshHeadingpubmed-meshheading:9399217-...lld:pubmed
pubmed-article:9399217pubmed:meshHeadingpubmed-meshheading:9399217-...lld:pubmed
pubmed-article:9399217pubmed:meshHeadingpubmed-meshheading:9399217-...lld:pubmed
pubmed-article:9399217pubmed:meshHeadingpubmed-meshheading:9399217-...lld:pubmed
pubmed-article:9399217pubmed:meshHeadingpubmed-meshheading:9399217-...lld:pubmed
pubmed-article:9399217pubmed:meshHeadingpubmed-meshheading:9399217-...lld:pubmed
pubmed-article:9399217pubmed:meshHeadingpubmed-meshheading:9399217-...lld:pubmed
pubmed-article:9399217pubmed:meshHeadingpubmed-meshheading:9399217-...lld:pubmed
pubmed-article:9399217pubmed:meshHeadingpubmed-meshheading:9399217-...lld:pubmed
pubmed-article:9399217pubmed:meshHeadingpubmed-meshheading:9399217-...lld:pubmed
pubmed-article:9399217pubmed:meshHeadingpubmed-meshheading:9399217-...lld:pubmed
pubmed-article:9399217pubmed:meshHeadingpubmed-meshheading:9399217-...lld:pubmed
pubmed-article:9399217pubmed:year1997lld:pubmed
pubmed-article:9399217pubmed:articleTitleTolcapone added to levodopa in stable parkinsonian patients: a double-blind placebo-controlled study. Tolcapone in Parkinson's Disease Study Group II (TIPS II).lld:pubmed
pubmed-article:9399217pubmed:affiliationDepartment of Neurology, Arhus University Hospital, Denmark.lld:pubmed
pubmed-article:9399217pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:9399217pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:9399217pubmed:publicationTypeRandomized Controlled Triallld:pubmed
pubmed-article:9399217pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9399217lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9399217lld:pubmed